SGLT2 inhibitors × glycemic control

TrialJournal of diabetes investigation2016

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.

Chieh-Hsiang Lu et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 171 people · 2016

No range given

Reported lower glycemic control, no range given

−0.46percentage points

As reported

difference −0.46 %, no interval

One number in the abstract

the abstract, start to end

respectively (between-group difference -0.46%, P < 0.001).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−0.46
SGLT2 inhibitorsGlycemic control

SGLT2 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.920.92 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

36 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 27330723